Even after rebounding, it's in a stalemate. It was announced that the company plans to announce data such as immune tolerance and sustained therapeutic effects of MDL-101 (epigenome editing technology using CRISPR) at the Fifth Next-Generation Gene Therapy Immunogenicity Summit. It is a data strongly indicating the safety of systemic administration of vectors expressing exogenous proteins, and suggests that MDL-101 has the potential to be an innovative therapeutic method for LAMA2-CMD and that CRISPR-GNDM is a groundbreaking technology platform applicable to systemic hereditary diseases.
モダリス---反発後もみ合い、「MDL-101」の前臨床データなどを発表予定
Modaris - Expected to announce preclinical data for 'MDL-101' despite a tug-of-war after the rebound.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.